HIV-1-infection
Conditions
Brief summary
To explore whether gut microbiota would impact CD4 T cells recovery in HIV-infected patients on antiretroviral therapy (ART). We prospectively enroll patients initiate ART and collect their fecal at followup for one year.
Interventions
First line antiretroviral therapy as recommended in China, e.g. tenofovir lamivudine and efavirenz
Sponsors
Shanghai Public Health Clinical Center
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* Confirmed HIV infection * Antiretroviral therapy naive * CD4 T cell counts\<350cells/mm3 * Agree to participate
Exclusion criteria
* Don't want to start antiretroviral therapy * Cocurrent cancer or opportunistic infection * Liver diseases * received antibiotics within four weeks of enrollment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Immune recovery | 48 weeks | Cluster of differentiation 4 (CD4) T cells increased \>25% or to higher than 350 cells/mm3 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| HIV viral load | 48 weeks | Viral load below limitation of detection |
| Microbiota composition | week 0 and 48 | Gut microbiota composition |
Countries
China
Contacts
Primary ContactJun Chen
Backup ContactHongzhou Lu
Outcome results
None listed